Belbuca contains buprenorphine as its active ingredient, so the drug itself is chemically identical. But Belbuca is not interchangeable with other buprenorphine products. It uses a specific delivery method, comes in much smaller doses, and is approved for a different purpose than the buprenorphine formulations most people are familiar with. The distinction matters for how the drug works in your body, what it treats, and how it’s prescribed.
Same Drug, Different Product
The active ingredient in Belbuca is buprenorphine hydrochloride, the exact same molecule found in products like Suboxone, Sublocade, and Butrans. Buprenorphine is a partial opioid, meaning it activates pain-relieving receptors in the brain but with a built-in ceiling effect. It doesn’t ramp up the way full opioids like oxycodone or morphine do, which gives it a lower risk of respiratory depression at higher doses.
Where Belbuca differs from other buprenorphine products is in nearly everything else: the delivery system, the dose range, the approved use, and whether it includes additional ingredients like naloxone. Thinking of “buprenorphine” as one thing is a bit like thinking of “insulin” as one thing. The molecule matters, but so does how it gets into your body and what condition it’s designed to treat.
What Belbuca Is Approved For
Belbuca is FDA-approved specifically for chronic pain severe enough to require daily, around-the-clock opioid treatment. It is not approved for opioid use disorder (OUD), which is the indication most people associate with buprenorphine. Products like Suboxone (a sublingual film combining buprenorphine with naloxone) and Sublocade (a monthly injection) are the formulations designed for OUD treatment.
This distinction has real consequences. A prescription for Belbuca signals to pharmacies, insurers, and prescribers that the goal is pain management, not addiction treatment. The two uses involve different dosing strategies, different monitoring, and often different specialists.
How the Buccal Film Works
Belbuca is a small film that sticks to the inside of your cheek. To apply it, you wet the inside of your cheek with your tongue or a sip of water, press the yellow side of the film against the cheek lining, hold it for five seconds, and leave it alone. The film typically dissolves completely within 30 minutes. You shouldn’t eat, drink, or move the film around with your tongue while it’s dissolving.
This buccal (cheek) delivery route is what gives Belbuca its relatively high bioavailability. Roughly 46 to 65 percent of the buprenorphine in each film makes it into your bloodstream, depending on the dose. For comparison, swallowing buprenorphine as a pill would deliver far less of the drug because it gets heavily broken down by the liver before reaching circulation. The cheek lining bypasses that problem, absorbing the drug directly into nearby blood vessels.
Dose Range Compared to Other Products
One of the most obvious differences is the dose. Belbuca comes in seven strengths: 75, 150, 300, 450, 600, 750, and 900 micrograms. Those are micrograms, not milligrams. For context, a single Suboxone film for OUD treatment contains 2, 4, 8, or 12 milligrams of buprenorphine. That means even the highest Belbuca dose (900 micrograms, or 0.9 milligrams) is a fraction of a standard OUD dose.
This isn’t a mistake or a sign that Belbuca is weaker as a product. The buccal delivery system is efficient enough that smaller amounts of the drug produce meaningful pain relief. In a head-to-head comparison conducted during FDA review, a 900-microgram Belbuca film produced peak blood levels of about 1.32 ng/mL, while an 8-milligram sublingual buprenorphine tablet produced peak levels of 6.73 ng/mL. The sublingual tablet delivered roughly five times the blood concentration, but it also contained nearly nine times as much drug. Milligram for milligram, the buccal route is more efficient.
How Belbuca Compares to Butrans
Butrans is another buprenorphine product used for chronic pain, but it’s a transdermal patch worn on the skin for seven days at a time. It delivers buprenorphine continuously in doses measured as micrograms per hour (ranging from 5 to 20 mcg/hr). Belbuca, by contrast, is applied to the cheek twice daily. Both treat chronic pain, but the experience of using them is quite different. Some people prefer the convenience of a weekly patch, while others find patches irritating to the skin or difficult to keep in place.
Neither Belbuca nor Butrans contains naloxone. Suboxone and its generic equivalents include naloxone as a deterrent against misuse, but that combination is specific to OUD formulations.
Dental Risks With Buccal and Sublingual Use
In 2022, the FDA issued a warning about dental problems linked to buprenorphine products that dissolve in the mouth. This includes both buccal films like Belbuca and sublingual tablets or films used for OUD. Reports included tooth decay, cavities, oral infections, and tooth loss, even in patients who had no prior dental issues.
The likely mechanism involves prolonged exposure of teeth and gums to the acidic environment created as the film dissolves. If you use Belbuca, the FDA recommends taking a large sip of water after the film has fully dissolved, gently swishing it around your teeth and gums, and swallowing. Wait at least one hour before brushing your teeth, since brushing too soon can damage enamel that’s been temporarily softened by the acidic exposure. Regular dental checkups become especially important while you’re on this medication.
Controlled Substance Classification
All buprenorphine products, including Belbuca, are classified as Schedule III controlled substances by the DEA. This places them in a lower risk category than Schedule II opioids like oxycodone, hydrocodone, and fentanyl. Schedule III means the drug has a recognized potential for abuse but a lower risk of physical dependence compared to the stronger schedules. In practical terms, Schedule III medications can be prescribed with refills, while Schedule II drugs require a new prescription each time.
Buprenorphine’s partial opioid properties are the reason for this classification. Because the drug has a ceiling effect on respiratory depression, the overdose risk is lower than with full opioids, though it’s not zero, particularly when combined with sedatives like benzodiazepines or alcohol.
Why the Distinction Matters
If your doctor prescribes Belbuca, you’re getting buprenorphine, but you’re not getting the same thing as someone taking Suboxone for opioid dependence or wearing a Butrans patch. The dose, the delivery system, and the clinical goal are all different. Pharmacies cannot substitute one buprenorphine product for another without a new prescription. Insurance coverage also varies significantly between formulations, so a prior authorization for one product doesn’t automatically transfer to another.
If you’re switching from a different opioid to Belbuca, your provider will calculate an equivalent dose using a conversion factor. One milligram of buccal or sublingual buprenorphine is roughly equivalent to 30 milligrams of oral morphine. But these conversions are approximations, not exact math, and doses are typically reduced during the transition to account for differences in how your body responds to a new opioid.